TuHURA Biosciences (NASDAQ:HURA - Get Free Report) had its price objective reduced by analysts at HC Wainwright from $13.00 to $12.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's target price indicates a potential upside of 233.80% from the stock's current price. HC Wainwright also issued estimates for TuHURA Biosciences' Q3 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.09) EPS and Q2 2027 earnings at ($0.09) EPS.
A number of other equities research analysts also recently issued reports on HURA. RODMAN&RENSHAW upgraded shares of TuHURA Biosciences to a "strong-buy" rating in a research report on Thursday, December 19th. Rodman & Renshaw started coverage on TuHURA Biosciences in a report on Thursday, December 19th. They set a "buy" rating and a $11.00 price objective for the company.
Check Out Our Latest Stock Analysis on TuHURA Biosciences
TuHURA Biosciences Stock Down 1.2 %
Shares of HURA traded down $0.05 during trading hours on Thursday, reaching $3.60. The company had a trading volume of 73,551 shares, compared to its average volume of 273,883. TuHURA Biosciences has a 12-month low of $1.80 and a 12-month high of $7.93. The firm has a 50 day moving average of $3.41.
Hedge Funds Weigh In On TuHURA Biosciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Accent Capital Management LLC purchased a new position in shares of TuHURA Biosciences during the 4th quarter worth approximately $29,000. TT Capital Management LLC acquired a new stake in TuHURA Biosciences during the 4th quarter valued at $41,000. Jefferies Financial Group Inc. acquired a new stake in TuHURA Biosciences during the 4th quarter valued at $54,000. Bank of America Corp DE purchased a new position in TuHURA Biosciences during the fourth quarter worth $59,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of TuHURA Biosciences in the fourth quarter worth $61,000. Institutional investors and hedge funds own 0.62% of the company's stock.
About TuHURA Biosciences
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
See Also
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
